Education
About Us
Working with TipRanks
Follow Us
Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
AARD Analyst Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AARD Stock 12 Month Forecast
Average Price Target
$33.38
▲(139.80% Upside)
| Highest Price Target$50.00 | Average Price Target$33.38 | Lowest Price Target$18.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Buy
―
Initiated
12/12/25
Aardvark Therapeutics: Innovative Therapies for PWS and Obesity with Significant Market PotentialWe view the mechanism as having a strong biological rationale and as differentiated with PWS. The incorporation of a dipeptidyl peptidase 4 inhibitor in ARD-201 could enhance the asset’s efficacy by preventing degradation of incretins, such as GLP-1 and GIP. Pending clinical data, this could offer an alternative mechanism for addressing obesity, which is currently dominated by GLP-1 receptor agonist (GLP-1RA) based modalities.
H.C. Wainwright
$40
Buy
187.36%
Upside
Reiterated
12/11/25
Aardvark Therapeutics' Promising Progress and Market Potential: Analyst Recommends BuyValuation and Risks. We have employed a discounted cash flow (DCF)-based valuation methodology to assess Aardvark Therapeutics' prospects. This employs a 12% discount rate and 2% terminal growth rate, along with a 29.84% effective tax rate. We assign a 40% probability of approval (POA) to ARD-101 in PWS and a 30% POA to this asset in HO. In addition, we ascribe a 20% POA to ARD-201 in mass market obesity and metabolic indications.
BTIG
$26
Buy
86.78%
Upside
Reiterated
12/11/25
Analysts' Top Healthcare Picks: Aardvark Therapeutics, Inc. (AARD), Eli Lilly & Co (LLY)We view this reading positively to ARD-101's overall safety and efficacy profile to date, with topline data still expected 3Q26. Additionally, Rhythm Pharmaceuticals (RYTM, NR) announced ph 2 data for setmelanotide in PWS showing positive signals in both BMI and hyperphagia reduction, sufficient to advance to ph 3. While AARD is focused on hyperphagia, RYTM is pursuing the BMI angle. Overall, the data did not demonstrate a clear efficacy win over ARD-101, and we continue to see space for multiple players in PWS.
Raymond James
$47
Buy
237.64%
Upside
Initiated
12/02/25
Stifel Nicolaus
$24
Buy
72.41%
Upside
Reiterated
11/14/25
Cantor Fitzgerald
$50
Buy
259.20%
Upside
Reiterated
11/13/25
RBC Capital
$19→$18
Buy
29.31%
Upside
Reiterated
11/13/25
Morgan Stanley
$29
Buy
108.33%
Upside
Reiterated
11/04/25
Promising Potential of Aardvark Therapeutics: Buy Rating Based on ARD-201 and ARD-101 DevelopmentsWe note that ARD-101 is being developed for the treatment of hyperphagia associated with Prader-Willi syndrome (PWS) for which with Ph3 HERO study is currently enrolling patients and is expected to read out in 3Q26.
JonesTrading
$33
Buy
137.07%
Upside
Initiated
09/30/25
Bank of America Securities
$26→$25
Buy
79.60%
Upside
Reiterated
08/28/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Buy
―
Initiated
12/12/25
Aardvark Therapeutics: Innovative Therapies for PWS and Obesity with Significant Market PotentialWe view the mechanism as having a strong biological rationale and as differentiated with PWS. The incorporation of a dipeptidyl peptidase 4 inhibitor in ARD-201 could enhance the asset’s efficacy by preventing degradation of incretins, such as GLP-1 and GIP. Pending clinical data, this could offer an alternative mechanism for addressing obesity, which is currently dominated by GLP-1 receptor agonist (GLP-1RA) based modalities.
H.C. Wainwright
$40
Buy
187.36%
Upside
Reiterated
12/11/25
Aardvark Therapeutics' Promising Progress and Market Potential: Analyst Recommends BuyValuation and Risks. We have employed a discounted cash flow (DCF)-based valuation methodology to assess Aardvark Therapeutics' prospects. This employs a 12% discount rate and 2% terminal growth rate, along with a 29.84% effective tax rate. We assign a 40% probability of approval (POA) to ARD-101 in PWS and a 30% POA to this asset in HO. In addition, we ascribe a 20% POA to ARD-201 in mass market obesity and metabolic indications.
BTIG
$26
Buy
86.78%
Upside
Reiterated
12/11/25
Analysts' Top Healthcare Picks: Aardvark Therapeutics, Inc. (AARD), Eli Lilly & Co (LLY)We view this reading positively to ARD-101's overall safety and efficacy profile to date, with topline data still expected 3Q26. Additionally, Rhythm Pharmaceuticals (RYTM, NR) announced ph 2 data for setmelanotide in PWS showing positive signals in both BMI and hyperphagia reduction, sufficient to advance to ph 3. While AARD is focused on hyperphagia, RYTM is pursuing the BMI angle. Overall, the data did not demonstrate a clear efficacy win over ARD-101, and we continue to see space for multiple players in PWS.
Raymond James
$47
Buy
237.64%
Upside
Initiated
12/02/25
Stifel Nicolaus
$24
Buy
72.41%
Upside
Reiterated
11/14/25
Cantor Fitzgerald
$50
Buy
259.20%
Upside
Reiterated
11/13/25
RBC Capital
$19→$18
Buy
29.31%
Upside
Reiterated
11/13/25
Morgan Stanley
$29
Buy
108.33%
Upside
Reiterated
11/04/25
Promising Potential of Aardvark Therapeutics: Buy Rating Based on ARD-201 and ARD-101 DevelopmentsWe note that ARD-101 is being developed for the treatment of hyperphagia associated with Prader-Willi syndrome (PWS) for which with Ph3 HERO study is currently enrolling patients and is expected to read out in 3Q26.
JonesTrading
$33
Buy
137.07%
Upside
Initiated
09/30/25
Bank of America Securities
$26→$25
Buy
79.60%
Upside
Reiterated
08/28/25
Best Analysts Covering Aardvark Therapeutics, Inc.
1 Month
xxx
Success Rate
3/4 ratings generated profit
Average Return
+9.00%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +9.00% per trade.
3 Months
xxx
Success Rate
4/5 ratings generated profit
Average Return
+21.16%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +21.16% per trade.
1 Year
Success Rate
4/4 ratings generated profit
Average Return
+41.48%
reiterated a buy rating last month
Copying Joshua Schimmer's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +41.48% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
Average Return
+41.48%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +41.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AARD Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Nov 25
Dec 25
Strong Buy
6
9
11
18
16
Buy
0
0
0
0
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
9
11
18
17
Each month's total comprises the sum of three months' worth of ratings.
AARD Financial Forecast
AARD Stock Forecast FAQ
What is AARD’s average 12-month price target, according to analysts?
Based on analyst ratings, Aardvark Therapeutics, Inc.’s 12-month average price target is 33.38.
What is AARD’s upside potential, based on the analysts’ average price target?
Aardvark Therapeutics, Inc. has 139.80% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AARD a Buy, Sell or Hold?
Aardvark Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
What is Aardvark Therapeutics, Inc.’s price target?
The average price target for Aardvark Therapeutics, Inc. is 33.38. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $18.00. The average price target represents 139.80% Increase from the current price of $13.92.
The highest analyst price target is $50.00 ,the lowest forecast is $18.00. The average price target represents 139.80% Increase from the current price of $13.92.
What do analysts say about Aardvark Therapeutics, Inc.?
Aardvark Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of AARD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.